Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 3venetoclax 2vactosertib 1regorafenib 1fludarabine phosphate 1fludarabine 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1X-Rays 1TAK-243 1Photons 1Melphalan 1KB004 1Interleukin-2 1IL32 protein, human 1Cyclophosphamide 1CYC065 1CA-4948 1Biopsy 1Azacitidine 1Ascorbic Acid 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Myelodysplastic Syndromes × TAK-243 × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡